April 12th 2024
Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Expert Says Olaparib Label Needs Expansion
May 5th 2015The FDA’s recent approval of olaparib for women with BRCA-mutated advanced ovarian cancer marks a significant therapeutic advance for women with the malignancy, but the specific indication is far too restrictive and the drug should be offered to many more patients.
Read More
A Little STING May Enhance the Immune System Against Cancer
April 25th 2015Despite their promise, checkpoint inhibitors are not effective in every patient, and research suggests the STING (stimulator of interferon genes) pathway may hold important clues as to why some tumors fail to respond.
Read More
Dr. Monk Discusses Vascular Disrupting Agents in Ovarian Cancer
April 21st 2015To gain insight into this novel approach and its potential benefit, Targeted Oncology interviewed Bradley J. Monk, MD, FACOG, FACS, who presented phase II results at the 2015 SGO's Annual Meeting on Women's Cancer.
Read More
Survival Advantage Seen With IP Chemotherapy for Ovarian Cancer
April 2nd 2015Intraperitoneal (IP) chemotherapy offers a median 10-month survival advantage over IV chemotherapy for women with advanced ovarian cancer. Result from a retrospective analysis were recently published in the Journal of Clinical Oncology.
Read More
Primary Debulking Surgery for Ovarian Cancer Riskier Than NACT-IDS Regimen
April 1st 2015In a single-institution randomized prospective controlled trial of women with advanced epithelial ovarian cancer, 52.6% of patients in the PDS study arm had major complications with an MSKCC score of 3 or greater.
Read More
Fosbretabulin Plus Bevacizumab Improves PFS, Doubles Hypertension in Ovarian Cancer
March 31st 2015The addition fosbretabulin tromethamine to bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in pretreated patients with recurrent ovarian cancer enrolled in the phase II GOG186i study.
Read More
FANG Vaccine Markedly Decreases Disease Recurrence in Phase II Ovarian Cancer Trial
March 29th 2015A 2:1 open-label phase II trial of the FANG vaccine achieved a marked delay in time to progression, in all 14 of 21 patients with stage III/IV ovarian cancer who participated. The other 7 patients did not receive the vaccine.
Read More